Yang Jir-Jei, Yin Jiu-Haw, Yang Ding-I
Institute of Neuroscience, Tzu Chi University, Hualien, Taiwan.
Neurosci Lett. 2007 May 11;418(1):106-10. doi: 10.1016/j.neulet.2007.03.011. Epub 2007 Mar 12.
1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) kills tumor cells via multiple actions including alkylation and carbamoylation. Previously, we have reported that formation of S-nitrosoglutathione (GSNO) in glioma cells overexpressing inducible nitric oxide synthase (iNOS) contributed to nitric oxide (NO)-dependent carbamoylating chemoresistance against BCNU. To further characterize the effects of NO on alkylating cytotoxicity, colony formation assay was applied to evaluate the effects of various NO donors on rat C6 glioma cells challenged with alkylating agents. We demonstrate that NO donors including GSNO, diethylamine NONOate (DEA/NO), and sodium nitroprusside (SNP) substantially reduced the extent of colony formation in glioma cells treated with alkylating agents, namely methyl methanesulfonate (MMS), N-methyl-N-nitrosourea (MNU), and N-ethyl-N-nitrosourea (ENU). Without alkylating agents these NO-releasing agents alone had no effects on clongenic potential of rat C6 glioma cells. Among these three NO donors used, the effectiveness in potentiating alkylating cytotoxicity is in the order of "GSNO>DEA/NO>SNP" when applied at the same dosages. GSNO also exerted similar synergistic actions reducing the extents of colony formation when co-administrated with 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazine (compound #1), another alkylating agent that mimics the chloroethylating action of BCNU. Together with our previous findings, we propose that NO donors may be used as adjunct chemotherapy with alkylating agents for such malignant brain tumors as glioblastoma multiforme (GBM). In contrast, production of NO as a result of iNOS induction, such as that occurring after surgical resection of brain tumors, may compromise the efficacy of carbamoylating chemotherapy.
1,3-双(2-氯乙基)-1-亚硝基脲(BCNU)通过包括烷基化和氨甲酰化在内的多种作用杀死肿瘤细胞。此前,我们报道过在过表达诱导型一氧化氮合酶(iNOS)的胶质瘤细胞中形成S-亚硝基谷胱甘肽(GSNO)有助于对BCNU产生一氧化氮(NO)依赖性的氨甲酰化化疗耐药性。为了进一步表征NO对烷基化细胞毒性的影响,采用集落形成试验来评估各种NO供体对用烷基化剂处理的大鼠C6胶质瘤细胞的影响。我们证明,包括GSNO、二乙胺NONOate(DEA/NO)和硝普钠(SNP)在内的NO供体显著降低了用烷基化剂即甲磺酸甲酯(MMS)、N-甲基-N-亚硝基脲(MNU)和N-乙基-N-亚硝基脲(ENU)处理的胶质瘤细胞中的集落形成程度。在没有烷基化剂的情况下,这些释放NO的试剂单独对大鼠C6胶质瘤细胞的克隆形成潜力没有影响。在使用的这三种NO供体中,当以相同剂量应用时,增强烷基化细胞毒性的有效性顺序为“GSNO>DEA/NO>SNP”。当与1,2-双(甲基磺酰基)-1-(2-氯乙基)-肼(化合物#1,另一种模拟BCNU氯乙基化作用的烷基化剂)共同给药时,GSNO也发挥了类似的协同作用,降低了集落形成程度。结合我们之前的研究结果,我们提出NO供体可作为烷基化剂的辅助化疗药物用于多形性胶质母细胞瘤(GBM)等恶性脑肿瘤。相反,iNOS诱导产生的NO,例如脑肿瘤手术切除后发生的情况,可能会损害氨甲酰化化疗的疗效。